Biobide strengthens its participation in international events

The schedule of Biobide scientists this spring is taken by very relevant international events in the sector. This week, the company acquired by Bionaturis Group and specialized in the use of zebrafish as animal model, presents two scientific posters in the Society of Environmental Toxicology and Chemistry (SETAC) Europe 26th Annual Meeting, 22-26 May 2016, at La Cite in Nantes, France.  Biobide also participates in the conference Measuring Behaviour 2016, hold in Dublin, with the research about the relationship between stress and exposure to light in this animal model.

R&D Management Director at Biobide, Arantza Muriana, will lead the presentation in SETAC 2016 of the posters titled ‘Testing toxicity of graphene oxide in zebrafish embryos’ and ‘Toxicity Profiling of Flame Retardants in Zebrafish’, both using zebrafish as animal model for varied toxicity and efficacy assays. The first one addresses the study of toxicity of graphene oxide, a very common material to produce goods used in our daily life, while the second one tackles the study of teratogenicity (possibilities of malformation in the development of the fetus in pregnant women), cardiotoxicity, hepatotoxicity and behavioral alterations in some flame retardants compounds found in everyday household products, to which people are regularly exposed. 

In addition to the presentation of these posters, Arantza Muriana and the Study Director, Virginia Caballero, will respond the large number of applications for one-to-one meetings in this event, considered the most important one in this specialized area in Europe. More than 2,000 scientists from 60 different countries will attend this event addressing relevant topics such as the climate change and contaminants or the production of cosmetics, among others.

Behaviour analysis

At the same time, Biobide takes part this week in the conference Measuring Behaviour 2016, considered the main […]

May 25th, 2016|Blog english, congress|Comments Off|

Bionaturis Group attends In-Cosmetics in Paris

Biobide, part of Bionaturis Group, is attending this week the European edition of the most relevant event on the Cosmetic sector worldwide: In-Cosmetics, hold in Paris on April, 12-14th. In addition, Biobide will have its own booth for the first time: B62.
R&D Management Director of Biobide, Arantza Muriana; and the Study Director, Virginia Caballero, are the delegates of Bionaturis Group in this forum that gathers more than 800 companies from 40 different countries during three hard-working days. Biobide has already arranged several high-level meetings with other exhibitors and visitors. In the latest edition, more than 8,000 people from 100 different nationalities visited this international event.
Besides its use in pharmaceutical, chemical and nutraceutical sectors, the versatility of the zebrafish lets Biobide to diversify to other sectors, such as cosmetic one. In particular, the company offers services of toxicity and efficacy assays, such as whitening/depigmenting efficacy, regeneration, angiogenesis inhibition and others, for the evaluation of cosmetic ingredients or final products. 
About Bionaturis Group
BBD BioPhenix-Biobide was incorporated into Bionaturis Group – which offers cutting-edge biotechnological drugs and services for human and animal health- in 2014. Considered an international benchmark in vaccines research, the biotechnological Group which envisions a global access to health is listed on the stock exchange (ticker BNT).

April 12th, 2016|Blog english, congress|Comments Off|

Biobide coordinates a course on zebrafish in the international annual conference of the Society of Toxicology (SOT) in New Orleans

Biobide (part of Bionaturis Group) participates in the most relevant scientific event devoted to toxicology and toxicity in the world, SOT and TOX Expo, held from 13rd March in New Orleans (USA). The participation of the company, which has grown in the latest meetings, includes the coordination of a course on zebrafish, the display of two scientific posters and the presence in the exhibition area with their own booth (number #1128).
The R&D Management Director at Biobide, Arantza Muriana, along with Mamta Behl from the NIH-NIEHS, is in charge of coordinating the course titled ‘Zebrafish As a Tool in Toxicology and Drug Discovery Screening’, held on March 13rd. The academic program, in which six experts will take part, aims to provide insight on the current developments in the use of zebrafish in the field of toxicology and drug safety and efficacy assessment, highlighting some ongoing challenges in the field. Specifically, Arantza Muriana will teach the chapter devoted to ‘Innovative Zebrafish Hepatotoxicity, Cardiotoxicity, and Neurobehavioral Toxicity Assays for Drug Selection”.
In addition to this course, Celia Quevedo, Study Director of Biobide will present on the 16th of March two scientific posters -number #1927 and #3299- with the collaboration of the company Stemina and the NIH-NIEHS, respectively. Both posters, which are included in the section titled Developmental Toxicology (Non Rodent)’, address the versatility of zebrafish to analyze toxicity, safety and efficacy of compounds.
“Our outstanding participation in such a relevant international congress as the SOT shows our expertise and confirms our position as partners of choice in the zebrafish sector worldwide”, Arantza Muriana has stated. Some months ago, Biobide set up a subsidiary in the USA, in the State of Maryland, and, recently they have signed a contract with […]

March 10th, 2016|Blog english, congress|Comments Off|

Bionaturis Group takes part in the North America SETAC Meeting, in Utah

Delegates of Bionaturis Group are attending this week the North American Meeting of the Environmental Toxicology Society (SETAC), held in Salt Lake City (Utah). This international event gathers more than 1,900 scientists, assessors, regulators and managers from 40 different countries to analyze the new issues in the sector through more than 1,600 presentations in only a week.

November 5th, 2015|Blog english, congress|Comments Off|

BBD BioPhenix technology attracts the interest of some companies in the SOT 2015 Annual Meeting and TOX Expo

The technology and the innovation of BBD BioPhenix (Bionaturis Group) in the use of zebrafish as animal model for efficacy and toxicity assays for drug screening has attracted the interest of several companies in the SOT 2015 Annual Meeting and TOX Expo, hold last week in San Diego (USA).

There, the R&D Managment Director, Arantza Muriana, and the General Manager, Andoni Cruz, have hold high-level meetings with pharmaceutical, cosmetics and chemical companies, as well as research agencies and significant international public institutions.

Besides its presence in exhibition and partnering areas, BBD BioPhenix presented a scientific poster titled ‘Screening of New Compounds That Alter Sleep-Wake State Alteration in Zebrafish’.

Nearly 7.000 professionals have joint in the latest edition of this important international meeting. For further information about it, please click here


March 31st, 2015|Blog english, congress|Comments Off|

BBD BioPhenix shows the advantages of zebrafish in the SOT 2015 Annual Meeting and TOX Expo

Arantza Muriana, R&D Management Director at BBD BioPhenix (Bionaturis Group), is the delegate in the SOT 2015 Annual Meeting and TOX Expo hold from 22nd March in San Diego (USA). BBD BioPhenix –an international reference company in drug screening and the use of zebrafish as animal model in efficacy and toxicity assays for pharmaceutical, biotechnological, chemical and cosmetic sectors, among others- is one of the 350 companies in the world attending this international event that every year receives more than 6.500 attendees.

Besides its presence in exhibition and partnering zones, BBD BioPhenix will present a scientific poster titled ‘Screening of New Compounds That Alter Sleep-Wake State Alteration in Zebrafish’, which describes trials done with some anxiolytic drugs to analize how they can alter Sleep-Wake States in humans, through the Behavior alterations´ assay in zebrafish.

“Attending to this event is very relevant to consolidate our international customers and establish new high-level contacts that let us growing more and more”, Arantza Muriana has stated. The versatility of zebrafish and the drug screening automated processes in BBD BioPhenix provide a better selection of candidates, decreasing time and cost in the new active compounds discovery.

For further information about the SOT 2015 Annual Meeting, organized by the Society of Toxicology, please click here

March 16th, 2015|Blog english, congress|Comments Off|

BBD BioPhenix works in cardiovascular, neurological and oncological diseases

Cardiovascular, neurological, oncological and SNC diseases can be researched by the zebrafish as animal model. BBD BioPhenix is developing several research projects in these areas applying the versatility and flexibility of this animal model.

In particular, in the cardiovascular area BBD intends to determine the therapeutic efficacy of some compounds in the treatment of some diseases besides identifying potential toxicities in the compounds to guarantee its safety.

In the oncological area, the experts of BBD BioPhenix aims to elucidate the tumor generation capacity and the teratoxicity of several compounds. Finally, they are also evaluating the neuroprotective and neurotoxic effects of certain compounds. For this, besides other techniques, they use the behavioral study in zebrafish, which contributes to the development of potential medicines against Alzheimer, among other neurodegenerative diseases.

“The unique advantages of zebrafish let us to design and launch important initiatives to progress in key discoveries to combat fatal pathologies”, the general manager of BBD BioPhenix, Andoni Cruz, states.

If you want to know more about BBD and its research projects, please click here.

January 16th, 2015|Blog english|Comments Off|

More capacity, results and higher speed by BBD BioPhenix automated platform

One of the main features of BBD BioPhenix (Bionaturis Group) is its automated high throughput screening platform. Due to this process developed by the company, they are able to reproduce the manual process of screening in a 96-well plate format ‘in vivo’ with zebrafish embryos.

There are many advantages for using this High-Content Screening platform (HCS):

-Higher analysis capacity: it is able to test more compounds in less time.
-Higher speed: the higher analysis capacity shortens testing times, with zebrafish embryos.
-More relevant information: the automated high-content screening in zebrafish (in vivo) gives more information than in vitro screenings, because the study is based on an organism rather than on an isolated cell.

“Our system is designed to offer the best results in the assays. We have the capability of developing some of the process in an automated way which is a great advantage for the specificity, sensitivity and repeatability of the results”, the general manager of BBD BioPhenix, Andoni Cruz, has stated.

If you want to know more about BBD BioPhenix, please click here.

October 23rd, 2014|Blog english|Comments Off|

“BioSpain 2014 has confirmed our position in the sector”

The delegates of Bionaturis Group at BioSpain 2014 has confirmed its positioning in the sector. In just three days they hold 40 one-to-one meetings to bolster existing business relationships and starting new collaborations for the next future.

“The quality and fruitfully meetings hold there demonstrate that we are in the right path. There are more and more multinational companies and institutions that are interested in working with us to move forward innovative solutions to the market. The unique features of the FLYLIFE platform to develop biological drugs and the versatility of the zebrafish animal model to optimize the drug discovery process were the hot topics during the meetings. A perfect blend between innovation and international expansion with a newborn effective presence in China makes us a perfect partner of choice”, the delegates have stated.

BBD BioPhenix presentation

Besides taking part as expositor within the Bionaturis Group stand (booth B9), BBD BioPhenix  gave a speech as part of the workshop titled “Key Enabling Technologies Applied to BIO”. In particular, R&D Manager, Arantza Muriana, delivered the conference “Key Enabling Technologies, fundamental part of zebrafish based screenings”.

In total, more than 3,000 partnering meetings has been hold in this forum and the presence of national and international investors has gained special relevance this edition. Check the highlights at #BioSpain2014.



September 30th, 2014|Blog english, Press english|Comments Off|

BBD BioPhenix diversifies Biotechnology application

One of the current challenges of BBD BioPhenix (acquired by Bionaturis) is gaining position in other markets different from pharmaceutical or veterinarian ones. The versatility of its services and the high capability of its  facilities to the tailor made requirements of its customers  make BBD an essential partner in drug discovery research for other sectors such as agrochemical, petrochemical, cosmetics and nutraceutical.

“We are already working in interesting projects outside the pharmaceutical arena thanks to the suitable features of the zebra fish model for active ingredients screening and our intention is going on this track”, R&D manager Arantza Muriana, states. BBD has a zebrafish facility able to grow up to 20,000 adults, including different lines that allow developing general and organ-specific toxicity and efficacy assays. In its lab, BBD is capable of developing biological and molecular assays under robust automatization processes.

“Nowadays, biotechnology can be applied to very different sectors and its more and more presence in our daily life”, the manager adds.

In case of BBD, the regulatory framework of the main markets is becoming an ally. Besides including the use of the zebrafish as a model in the guidelines for toxicity assays in chemical, agrochemical and cosmetic products, the limitations in the use of animals models for experimental assays are increasing (in accordance to the 3-R’s Rules: Replacement, Reducement and Refinement). These new guidelines do not exclude the use of zebrafish, because it is not considered as a superior animal model in these situations as long as the assays are made with embryos aged up to five days old. In this way, the use of the zebrafish model is becoming one of the alternatives with more applications.

Find below some of the OECD Guidelines including zebrafish as an […]

September 5th, 2014|Blog english|Comments Off|

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.